Overview

Chronic Kidney Disease Diagnostics Market Introduction

Chronic kidney disease symptoms like blood in urine, swollen joints, foamy urine, etc are seldom noticed by patients resulting in progressive loss of kidney functions and ultimately renal failure. Delayed diagnosis, lack of sufficient epidemiological data, the significant cost involved in end-stage renal diseases as well as mild kidney diseases have resulted in a substantial need for chronic kidney disease diagnostics. Apart from physical examination by healthcare professionals, certain diagnostics like biopsy or procedures like blood and urine test provide vital stats and early signs about patients neurological, blood vessels and organ conditions. Based on such diagnostic results healthcare professionals can effectively control the kidney symptoms and avoid the progression of chronic kidney disease in their patients.

Chronic Kidney Disease Diagnostics Market Overview

Factors boosting the chronic kidney disease diagnostics market:
•    Rising prevalence of kidney diseases
•    Increase in diabetic patients’ population 
•    Investments into R&D for kidney diseases diagnostic techniques
•    The ever-emerging healthcare sector 
•    Extensive use of processed food containing excess potassium and
•    The technological advancements in the healthcare diagnostics sector

Besides increased susceptibility of the ageing population due to degrading immune system, diabetics, cardiovascular issues are expected to fuel the growth of the global chronic kidney diseases diagnostics market during the forecast period.

North America holds the major revenue chunk in the global kidney diseases diagnostics market and is expected to grow at a thriving CAGR during the forecast period of 2019-2026. This is followed by Europe due to robust economic growth and investments in advanced diagnostic technologies. India, China and Vietnam from the APAC region are expected to demonstrate tremendous opportunities due to increased healthcare awareness, better household incomes and government aids to healthcare institutions. Rest of the world is expected to grow at a gradual CAGR and considerable market value in coming years. 

Key Market Players Metabolic Solutions Development Company, LLC, F. Hoffmann-La Roche Ltd, Otsuka Holdings Co. Ltd, Eli Lilly and Company, Kadmon Corporation LLC, Kissei Pharmaceutical Co. Ltd, Siemens, Randox Laboratories,Nova Biomedical 
                                                  

Chronic Kidney Disease Diagnostics Market Segmentation:

By Type

•    Blood Test
•    Urine Test
•    Imaging
•    Others

By End-User

•    Hospitals
•    Clinics
•    Diagnostic labs 

By Region

•    North America
•    Latin America
•    Europe
•    Asia Pacific
•    Rest of the World
Competitive Landscape:  
•    Tier 1 players- established companies in the market with a major market share
•    Tier 2 players 
•    Emerging players which are growing rapidly 
•    New Entrants  

FutureWise Key Takeaways 
•    Growth prospects
•    SWOT analysis 
•    Key trends 
•    Key data-points affecting market growth 

Objectives of the Study: 
•    To provide with an exhaustive analysis on the global chronic kidney disease diagnostics market on the basis of type, end user, and region
•    To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
•    To evaluate and forecast micro-markets and the overall market 
•    To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East
•    To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
•    Profiling of companies to evaluate their market shares, strategies, financials and core competencies  

Table of Contents

1. Market Introduction
         1.1. Objectives of the Study 
         1.2. Market Definition 
         1.3. Market Scope 
                1.3.1. Years Considered for the Study
                1.3.2. Market Covered
         1.4. Currency 
         1.5. Limitations 
         1.6. Stakeholders 
 2.  Research Methodology 
         2.1. Research Data 
                2.1.1. Secondary Data
                           2.1.1.1. Key Data from Secondary Sources
                2.1.2. Primary Data
                           2.1.2.1. Key Data from Primary Sources
         2.2. Market Size Estimation 
         2.3. Market Breakdown and Data Triangulation 
         2.4. Assumptions for the Study  
3. Executive Summary
         3.1. Market Outlook
         3.2. Segment Outlook
         3.3. Competitive Insights
4. Global Chronic Kidney Disease Diagnostics Market Variables, Trends & Scope
         4.1. Market Lineage Outlook
         4.2. Penetration and Growth Prospect Mapping
         4.3. Industry Value Chain Analysis
         4.4. Cost Analysis Breakdown
         4.5. Technology Overview
         4.6. Regulatory Framework
                 4.6.1. Reimbursement Framework
                 4.6.2. Standards and Compliances
5. Global Chronic Kidney Disease Diagnostics Market Overview
         5.1. Market Dynamics
                 5.1.1. Market Driver Analysis
                            5.1.1.1. Increasing focus of Chronic Kidney Disease Diagnostics Companies on Brand Protection
                            5.1.1.2. Untapped Opportunities in Emerging Regions
                 5.1.2. Market Restraint Analysis
                            5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
                 5.1.3. Industry Challenges
                            5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Global Chronic Kidney Disease Diagnostics Market Analysis Tools
         6.1. Industry Analysis - Porter’s
                 6.1.1. Supplier Power
                 6.1.2. Buyer Power
                 6.1.3. Substitution Threat
                 6.1.4. Threat from New Entrants
                 6.1.5. Competitive Rivalry
         6.2. Pestel Analysis
                 6.2.1. Political Landscape
                 6.2.2. Environmental Landscape
                 6.2.3. Social Landscape
                 6.2.4. Technology Landscape
                 6.2.5. Legal Landscape
         6.3. Major Deals And Strategic Alliances Analysis
                 6.3.1. Joint Ventures
                 6.3.2. Mergers and Acquisitions
                 6.3.3. Licensing and Partnership
                 6.3.4. Technology Collaborations
                 6.3.5. Strategic Divestments
         6.4. Market Entry Strategies
         6.5. Case Studies
7. Global Chronic Kidney Disease Diagnostics Market, By Type Historical Analysis and Forecast 2020-2027 (USD Million)
         7.1. Blood Test
         7.2. Urine Test
         7.3. Imaging
         7.4 Others
8. Global Chronic Kidney Disease Diagnostics Market, By End User Historical Analysis and Forecast 2020-2027 (USD Million)
         8.1.  Hospitals 
         8.2.  Clinics
         8.3. Diagnostic labs     
9. North America Market Analysis 2012–2019 and Forecast 2020–2027 (USD Million)
         9.1. Introduction
         9.2. Historical Market Size (USD Million) Analysis By Country, 2012-2019
                 9.2.1. U.S.A
                 9.2.2. Canada
                 9.2.3. Mexico
         9.3. Market Size (USD Million) Forecast for North America 2020-2027 
10. Latin America Market Analysis 2012–2019 and Forecast 2020–2027 (USD Million)
         10.1. Introduction
         10.2. Historical Market Size (USD Million) Analysis By Country, 2012-2019
                   10.2.1. Brazil
                   10.2.2. Venezuela
                   10.2.3. Argentina
                   10.2.4. Rest of Latin America
         10.3. Market Size (USD Million) Forecast for Latin America 2020-2027  
11. Europe Market Analysis 2012–2019 and Forecast 2020–2027 (USD Million)
         11.1. Introduction
         11.2. Historical Market Size (USD Million) Analysis By Country, 2012-2019
                   11.2.1. Germany
                   11.2.2. U.K
                   11.2.3. France
                   11.2.4. Italy
                   11.2.5. Spain
                   11.2.6. Russia
                   11.2.7. Poland
                   11.2.8. Rest of Europe
         11.3. Market Size (USD Million) Forecast for Europe 2020-2027
12. Asia Pacific Market Analysis 2012–2019 and Forecast 2020–2027 (USD Million)
         12.1. Introduction
         12.2. Historical Market Size (USD Million) Analysis By Country, 2012-2019
                   12.2.1. Japan
                   12.2.2. China
                   12.2.3. India
                   12.2.4. Australia and New Zealand
                   12.2.5. ASEAN
                   12.2.6. Rest of Asia Pacific
         12.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027
13. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
         13.1. Introduction
         13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
                   13.2.1. Saudi Arabia
                   13.2.2. UAE
                   13.2.3. South Africa
                   13.2.4. Egypt
         13.3. Market Size (USD Million) Forecast for MEA 2020-2027
14. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts)
         14.1. Metabolic Solutions Development Company
                  14.1.1. Company Overview
                  14.1.2. Product Portfolio
                  14.1.3. SWOT Analysis
                  14.1.4. Financial Overview
                  14.1.5. Strategic Overview
         14.2. Nova Biomedical
                  14.2.1. Company Overview
                  14.2.2. Product Portfolio
                  14.2.3. SWOT Analysis
                  14.2.4. Financial Overview
                  14.2.5. Strategic Overview
         14.3. F. Hoffmann-La Roche Ltd
                  14.3.1. Company Overview
                  14.3.2. Product Portfolio
                  14.3.3. SWOT Analysis
                  14.3.4. Financial Overview
                  14.3.5. Strategic Overview
         14.4. Otsuka Holdings Co. Ltd
                  14.4.1. Company Overview
                  14.4.2. Product Portfolio
                  14.4.3. SWOT Analysis
                  14.4.4. Financial Overview
                  14.4.5. Strategic Overview
         14.5 Eli Lilly and Company
                  14.5.1. Company Overview
                  14.5.2. Product Portfolio
                  14.5.3. SWOT Analysis
                  14.5.4. Financial Overview
                  14.5.5. Strategic Overview
         14.6 Kadmon Corporation LLC
                  14.6.1. Company Overview
                  14.6.2. Product Portfolio
                  14.6.3. SWOT Analysis
                  14.6.4. Financial Overview
                  14.6.5. Strategic Overview
         14.7. Kissei Pharmaceutical Co. Ltd
                  14.7.1. Company Overview
                  14.7.2. Product Portfolio
                  14.7.3. SWOT Analysis
                  14.7.4. Financial Overview
                  14.7.5. Strategic Overview
         14.8. Siemens
                  14.8.1. Company Overview
                  14.8.2. Product Portfolio
                  14.8.3. SWOT Analysis
                  14.8.4. Financial Overview
                  14.8.5. Strategic Overview
         14.9. Randox Laboratories
                  14.9.1. Company Overview
                  14.9.2. Product Portfolio
                  14.9.3. SWOT Analysis
                  14.9.4. Financial Overview
                  14.9.5. Strategic Overview
15. FutureWise SME Key Takeaway Points for Client

Tables

Figures